Approval · Notice of Compliance 10245 · 2009
SENSIPAR: Notice of Compliance 10245
Issued June 5, 2009
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 10245
- Date
- June 5, 2009
- Company
- Amgen Canada IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indications: For the reduction of hypercalcemia in patients with parathyroid carcinoma and for the reduction of clinically significant hypercalcemia, as defined by relevant treatment guidelines, in patients with primary HPT for whom parathyroidectomy is not clinically appropriate or is contraindicated
- Therapeutic class
- Calcimimetic agent
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SENSIPAR | Not yet assigned | — |
Medicinal ingredients
- CINACALCET HYDROCHLORIDE 30 MG per TAB
- CINACALCET HYDROCHLORIDE 60 MG per TAB
- CINACALCET HYDROCHLORIDE 90 MG per TAB